ArticleDiscover oncology2025
Integration of Mendelian randomization and transcriptome wide association studies for causal gene identification in ovarian cancer genetic architecture.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOvarian cancer remains one of the most lethal gynecological malignancies with limited understanding of its genetic architecture and causal mechanisms. While genome-wide association studies have identified numerous susceptibility loci, the causal relationships between gene expression and ovarian cancer risk remain poorly understood.
methodsWe conducted a comprehensive genetic analysis integrating two-sample Mendelian randomization (MR) and transcriptome-wide association studies (TWAS) using expression quantitative trait loci (eQTL) data from the GTEx project and ovarian cancer GWAS data from the Ovarian Cancer Association Consortium (OCAC). Summary-data-based Mendelian randomization (SMR) analysis was performed to assess causal relationships between gene expression and ovarian cancer risk. Additionally, we analyzed survival outcomes in 3595 ovarian cancer patients from the SEER database to examine the clinical implications of radiation timing and constructed a prognostic nomogram incorporating genetic and clinical factors.
resultsMR analysis identified three genes with significant causal associations with ovarian cancer risk. GSTZ1 variant rs11621440 demonstrated a protective effect (OR = 0.999, 95% CI 0.999-1.000, FDR = 0.001), while PNP variant rs8015430 (OR = 1.006, 95% CI 1.002-1.010, FDR = 0.002) and KIAA1715 variant rs864697 (OR = 0.999, 95% CI 0.999-1.000, FDR = 0.002) showed increased risk associations. TWAS analysis revealed multiple genes with transcriptome-wide significant associations, including SIGLEC family genes (SIGLEC14, SIGLEC12, SIGLEC5) associated with increased risk through decreased expression, and metabolic genes (OCTN2, MSR1) associated with risk through increased expression. Survival analysis demonstrated that radiation timing significantly impacts prognosis, with postoperative radiation showing superior outcomes compared to preoperative radiation (HR = 1.49, 95% CI 1.23-1.82, p = 5.8 × 10
conclusionsThis study provides robust genetic evidence for causal relationships between specific gene expression patterns and ovarian cancer risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.